Proceedings of a GOG workshop on intraperitoneal therapy for ovarian cancer

被引：27

作者：

Alberts, D. S.

Markman, M.

Muggia, F.

Ozols, R. F.

Eldermire, E.

Bookman, M. A.

Chen, T.

Curtin, J.

Hess, L. M.

Liebes, L.

Young, R. C.

Trimble, E.

机构：

[1] Univ Arizona, Arizona Canc Ctr, Tucson, AZ 85724 USA

[2] Univ Texas, MD Anderson Canc Ctr, Houston, TX 77030 USA

[3] NYU, Inst Canc, New York, NY USA

[4] NYU, Sch Med, New York, NY USA

[5] Case Western Reserve Univ Hosp, Cleveland, OH 44106 USA

[6] NCI, Bethesda, MD 20892 USA

来源：

GYNECOLOGIC ONCOLOGY | 2006年 / 103卷 / 03期

关键词：

ovarian cancer; intraperitoneal chemotherapy; oncology;

D O I：

10.1016/j.ygyno.2006.09.012

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Ovarian cancer is the leading cause of gynecologic cancer deaths in the U.S. The concept of intraperitoneal ding delivery for therapy of intraperitoneal cancers, such as ovarian cancer, arose in the 1960s. The field of intraperitoneal cisplatin therapy for ovarian cancer was initiated in the late 1970s and early 1980s. The markedly improved survival data resulting from a phase III trial of intraperitoneal cisplatin for ovarian cancer in early 2006 led to an NCl Clinical Announcement and a Gynecologic Oncology Group-sponsored workshop on intraperitoneal therapy in January, 2006, in San Diego, California. The proceedings of this workshop summarize both research trial results and practical implementation issues associated with intraperitoneal therapy discussed at this workshop. (c) 2006 Elsevier Inc. All rights reserved.

引用

页码：783 / 792

页数：10

共 43 条

[1] Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer [J].

Alberts, DS ;

Liu, PY ;

Hannigan, EV ;

OToole, R ;

Williams, SD ;

Young, JA ;

Franklin, EW ;

ClarkePearson, DL ;

Malviya, VK ;

DuBeshter, B ;

Adelson, MD ;

Hoskins, WJ .

NEW ENGLAND JOURNAL OF MEDICINE, 1996, 335 (26) :1950-1955

[2] Intraperitoneal therapy for stage III ovarian cancer: A therapy whose time has come! [J].

Alberts, DS ;

Markman, M ;

Armstrong, D ;

Rothenberg, ML ;

Muggia, F ;

Howell, SB .

JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (19) :3944-3946

[3] Intraperitoneal cisplatin and paclitaxel in ovarian cancer [J].

Armstrong, DK ;

Bundy, B ;

Wenzel, L ;

Huang, HQ ;

Baergen, R ;

Lele, S ;

Copeland, LJ ;

Walker, JL ;

Burger, RA .

NEW ENGLAND JOURNAL OF MEDICINE, 2006, 354 (01) :34-43

[4] Intraperitoneal chemotherapy for ovarian carcinoma: Results of long-term follow-up [J].

Barakat, RR ;

Sabbatini, P ;

Bhaskaran, D ;

Revzin, M ;

Smith, A ;

Venkatraman, E ;

Aghajanian, C ;

Hensley, M ;

Soignet, S ;

Brown, C ;

Soslow, R ;

Markman, M ;

Hoskins, WJ ;

Spriggs, D .

JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (03) :694-698

[5]

CASPER ES, 1983, CANCER TREAT REP, V67, P235

[6]

DEDRICK RL, 1978, CANCER TREAT REP, V62, P1

[7] 2004 consensus statements on the management of ovarian cancer: final document of the 3rd International Gynecologic Cancer Intergroup Ovarian Cancer Consensus Conference (GCIG OCCC 2004) [J].

du Bois, A ;

Quinn, M ;

Thigpen, T ;

Vermorken, J ;

Avall-Lundqvist, E ;

Bookman, M ;

Bowtell, D ;

Brady, M ;

Casado, A ;

Cervantes, A ;

Eisenhauer, E ;

Friedlaender, M ;

Fujiwara, K ;

Grenman, S ;

Guastalla, JP ;

Harper, P ;

Hogberg, T ;

Kaye, S ;

Kitchener, H ;

Kristensen, G ;

Mannel, R ;

Meier, W ;

Miller, B ;

Neijt, JP ;

Oza, A ;

Ozols, R ;

Parmar, M ;

Pecorelli, S ;

Pfisterer, J ;

Poveda, A ;

Provencher, D ;

Pujade-Lauraine, E ;

Randall, M ;

Rochon, J ;

Rustin, G ;

Sagae, S ;

Stehman, F ;

Stuart, G ;

Trimble, E ;

Vasey, P ;

Vergote, I ;

Verheijen, R ;

Wagner, U .

ANNALS OF ONCOLOGY, 2005, 16 :7-12

[8] A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer [J].

du Bois, A ;

Lück, HJ ;

Meier, W ;

Adams, HP ;

Möbus, V ;

Costa, S ;

Bauknecht, T ;

Richter, B ;

Warm, M ;

Schröder, W ;

Olbricht, S ;

Nitz, U ;

Jackisch, C ;

Emons, G ;

Wagner, U ;

Kuhn, W ;

Pfisterer, J .

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2003, 95 (17) :1320-1330

[9] PHASE-I FEASIBILITY AND PHARMACOLOGICAL STUDY OF WEEKLY INTRAPERITONEAL PACLITAXEL - A GYNECOLOGIC-ONCOLOGY-GROUP PILOT-STUDY [J].

FRANCIS, P ;

ROWINSKY, E ;

SCHNEIDER, J ;

HAKES, T ;

HOSKINS, W ;

MARKMAN, M .

JOURNAL OF CLINICAL ONCOLOGY, 1995, 13 (12) :2961-2967

[10]

*GOG, 2006, IP CHEM ED MAT

← 1 2 3 4 5 →